Key Finding: Faeth Therapeutics, Inc. (NASDAQ: FTH) is a clinical-stage biotechnology company focused on cancer therapies, particularly its lead asset PIKTOR, which has experienced significant stock price appreciation and positive analyst coverage following its June 2026 rebranding and public listing transition.
Company Overview
Faeth Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing next-generation immunotherapies and targeted therapies for cancer and infectious diseases. Its pipeline centers on multi-node inhibition of the PI3K/AKT/mTOR (PAM) pathway, with lead candidate PIKTOR (an all-oral combination therapy) in development for endometrial and breast cancers, alongside Solnerstotug (a VISTA-targeting monoclonal antibody) and earlier-stage assets.
- Headquarters: Rockville, Maryland
- Employees: Approximately 29 (fact from multiple sources)
- CEO: Anand Parikh
- Website: www.faeththerapeutics.com
- Sector/Industry: Healthcare / Biotechnology
The company emphasizes pioneering multi-node PAM pathway inhibition, described as targeting one of the most frequently altered oncogenic pathways in cancer.
Company History
Key Timeline (Facts):
- Original Faeth Therapeutics co-founded in 2019 by Anand Parikh and others.
- Sensei Biotherapeutics, Inc. (predecessor) incorporated in 1999; previously focused on antibody therapies including VISTA and CD28 programs.
- February 2026: Sensei acquires Faeth Therapeutics in a transaction including a $200 million concurrent private placement; PIKTOR becomes lead asset.
- June 15, 2026: Stockholders approve name change from Sensei Biotherapeutics to Faeth Therapeutics, Inc.; ticker transitions to FTH (effective ~June 16, 2026) following reverse merger-like structure and preferred stock conversion.
This rebranding and capital infusion positioned the company as a well-capitalized public entity with a focused oncology pipeline.
Exact founding details of the original Sensei entity pre-2026 merger carry some ambiguity across sources regarding continuity of operations.
Recent News (as of July 2026)
- July 2, 2026: PIKTOR Trial targets advanced breast cancer with new combo approach (TipRanks).
- June 26, 2026: Initiated with Outperform rating by Baird (price target $57).
- June 22, 2026: Initiated with Buy rating by H.C. Wainwright.
- June 18, 2026: Launches new At-the-Market (ATM) equity program; files automatic mixed securities shelf.
- June 15, 2026: Official name change and ticker transition announcement.
- Multiple insider purchases reported in June 2026, signaling confidence.
News flow indicates strong momentum around clinical progress and financial positioning post-rebrand.
Stock Performance
Data as of close on July 9, 2026 (highly volatile biotech stock; prices fluctuate rapidly):
| Metric | Value |
|---|
| Closing Price | $32.54 (+16.13%) |
| Market Cap | ~$839 million |
| 52-Week Range | $6.33 – $36.76 |
| YTD Return | ~205% |
| 1-Year Return | ~256% |
| Avg. Daily Volume | ~60,000–122,000 shares |
| Analyst Consensus | Strong Buy (100% Buy ratings from 6 analysts) |
| Avg. Price Target | $54.50 (range $50–$60) |
| P/E Ratio (TTM) | Negative (unprofitable; ~ -0.23) |
Performance Context: Stock has shown explosive gains in 2026, outperforming the S&P 500 significantly, likely driven by the rebranding, capital raise, and clinical catalysts. Beta is low/negative (~ -0.26), indicating limited correlation with broader market.
Links for More Information
Data Limitations and Assumptions
- All financial and stock data reflects information available as of July 9–10, 2026; real-time prices and performance can change substantially.
- Focus is on NASDAQ:FTH (Faeth Therapeutics); a separate JSE:FTH.JO (Frontier Transport Holdings, South African logistics) exists but shows minimal overlap in recent searches and context.
- Pipeline status, trial results, and analyst targets are forward-looking and subject to clinical/regulatory uncertainties.
- Company history involves complex merger/rebranding events; minor discrepancies in pre-2026 founding details across sources.
- No dividend history; company remains pre-revenue with negative EPS.
Interpretation: The recent transformation and market enthusiasm suggest potential for continued volatility tied to clinical milestones. Investors should conduct independent due diligence.